Table 1.

Basic clinical characteristics and subgroup frequencies of CYB5Aalt positive and negative patients in cohort 1

	CYB5Aalt-status
	positive (n = 9)	negative (n = 41)
median BM blast count (%) at ID	88	92
median age at ID (years)	18	15
median time to REL (days)	615	744
samples
adult (n = 24)	5	19
pediatric (n = 26)	4	22
sex
male (n = 27)	4	23
female (n = 23)	5	18
molecular subgroup
NH (n = 4)	2	2
HeH (n = 6)	3	3
LH (n = 4)	1	3
Ph-like (n = 12)	1	11
DUX4r (n = 12)	0	12
Unknown (n = 3)	0	3
BCL2r (n = 2)	0	2
PAX5mut (n = 2)	0	2
PAX5r (n = 1)	0	1
MEF2Dr (n = 1)	0	1
MLLr (n = 2)	0	2
ZNF384f (n = 2)	0	2

Table 1 lists a comparison of characteristics for CYB5Aalt positive patients (n = 9) and negative patients (n = 41) in cohort 1 (n = 50). Characteristics include median bone marrow (BM) blast count, age, sex, frequencies of adult (n = 24) and pediatric patients (n = 26) and median time to REL. Further, frequencies of CYB5Aalt-positive and negative samples in the different molecular subtypes in cohort 1 are listed with total number of patients per subgroup in brackets, respectively